ABSTRACT
Mass vaccination is one of the most effective epidemic control measures. Because one’s vaccination decision is shaped by social processes, the pattern of vaccine uptake tends to show strong social and spatial heterogeneity, such as urban-rural divide and clustering. Examining through network perspectives, we develop a framework for estimating the impact of spatial vaccination heterogeneity on epidemic outbreaks. Leveraging fine-grained mobility data and computational models, we investigate two network effects—the “hub effect” (vaccinating mobility hubs reduces transmission) and the “homophily effect” (stronger homophily in vaccination rates increases transmission). Applying Bayesian deep learning and fine-grained epidemic simulations, our study suggests a negative effect of homophily and a positive effect of highly vaccinated hubs on reducing case counts for both the synthetic network and the U.S. mobility network. Our framework enables us to evaluate outcomes from various hypothetical spatial vaccine distributions and to study a hypothetical vaccination campaign strategy that targets a small number of regions with the largest gain in protective power using the data from January 2022. Our simulation suggests that our strategy can potentially prevent about 2.5 times more cases than a uniform strategy with an additional 1% of the population vaccinated. Notably, our simulation also shows that this strategy could even better protect vulnerable or disadvantaged communities through network effects than strategies that directly target them. Our study suggests that we need to examine the interplay between vaccination patterns and mobility networks beyond the overall vaccination rate, and that understanding geographical pattern of vaccine uptake could be just as important as improving the overall vaccination rate.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research is supported by Purdue Krannert School of Management and MIT Connection Science.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The source data is available from Safegraph https://www.safegraph.Acom/academics
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Equity issue discussed
Data Availability
All data produced are available online at https://github.com/yuany94/covid-vaccine